These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. Lau D; Magill ST; Aghi MK Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384 [TBL] [Abstract][Full Text] [Related]
9. Management of glioblastoma: State of the art and future directions. Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363 [TBL] [Abstract][Full Text] [Related]
11. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Bambury RM; Morris PG Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143 [TBL] [Abstract][Full Text] [Related]
12. From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. Zygogianni A; Protopapa M; Kougioumtzopoulou A; Simopoulou F; Nikoloudi S; Kouloulias V Clin Transl Oncol; 2018 Aug; 20(8):989-1003. PubMed ID: 29335830 [TBL] [Abstract][Full Text] [Related]
13. MRI characteristics and histological changes in glioblastoma after gene therapy. Weber FW; Floeth FW; Reifenberger G; Felsberg J; Aulich A; Kiwit JC; Bock WJ Front Radiat Ther Oncol; 1999; 33():244-52. PubMed ID: 10549494 [No Abstract] [Full Text] [Related]
14. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200 [TBL] [Abstract][Full Text] [Related]
15. Delayed response and survival from NovoTTF-100A in recurrent GBM. Villano JL; Williams LE; Watson KS; Ignatius N; Wilson MT; Valyi-Nagy T; Michals EA; Engelhard HH Med Oncol; 2013 Mar; 30(1):338. PubMed ID: 23307238 [TBL] [Abstract][Full Text] [Related]
17. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869 [TBL] [Abstract][Full Text] [Related]
18. Recurrent glioblastoma: who receives tumor specific treatment and how often? Steffens R; Semrau S; Lahmer G; Putz F; Lettmaier S; Eyüpoglu I; Buchfelder M; Fietkau R J Neurooncol; 2016 May; 128(1):85-92. PubMed ID: 26907492 [TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival. Lee J; Ahn SS; Chang JH; Suh CO Yonsei Med J; 2018 Mar; 59(2):194-201. PubMed ID: 29436186 [TBL] [Abstract][Full Text] [Related]